Phase 2 Thyroid Cancer Trial, Active, Not Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must have already enrolled in a related study (called APEC1621SC / NCT03155620) and been matched to this treatment based on a specific genetic change found in your cancer.
• You must be at least 12 months old and no older than 21 years old when joining the study.
• Your body surface area (a measure based on height and weight) must meet a minimum size requirement (confirm with trial site).
• Your cancer must be measurable on a scan (such as an MRI or CT), meaning there is at least one tumor that can be seen and measured; children with neuroblastoma may still qualify if their cancer shows up on a specific type of scan called an MIBG scan even if it cannot be measured in the usual way.
• You must be well enough to carry out at least some daily activities, as measured by a standard ability scale used for your age group.
• You must have recovered from side effects of any previous cancer treatments, and enough time must have passed since your last treatment (the exact waiting period depends on what type of treatment you had — confirm with trial site).
• You must never have received the study drug, tipifarnib, before.
• Your blood cell counts (white cells and platelets) must be at or above certain levels in the week before joining (specific numbers depend on whether your bone marrow is affected by cancer — confirm with trial site).
• Your kidneys must be working well enough, based on a blood or urine test done within the past week.
• Your liver must be working well enough, based on blood tests done within the past week.
• Your blood protein (albumin) level must be at or above a minimum level, based on a blood test done within the past week.
• If you have a seizure condition, you may still be eligible as long as it is well controlled with medication.
• Any nerve-related side effects from past treatments must be mild (grade 2 or lower).
• You must be able to swallow tablets whole or crushed and mixed into a drink or soft food, or receive them through a feeding tube.
• You (and/or your parent or legal guardian) must be willing and able to sign a consent form agreeing to take part.

Who may not be able to join:

• Women who are pregnant or breastfeeding cannot join this trial.
• Anyone who could become pregnant or father a child must agree to use two reliable forms of contraception during treatment and for at least 4 weeks after the last dose; males who wish to preserve their fertility should discuss sperm banking before starting treatment.
• You are not eligible if you are taking steroid medications (such as prednisone) unless you have been on a stable or reducing dose for at least 7 days before joining (or at least 14 days if the steroids were used to treat side effects of a previous cancer therapy).
• You cannot join if you are currently taking part in another clinical trial using an experimental drug.
• You cannot join if you are currently receiving any other cancer treatment.
• You are not eligible if you are taking medications to prevent graft-versus-host disease after a bone marrow transplant (such as cyclosporine or tacrolimus).
• You cannot join if you are taking certain medications that strongly affect how the body processes the study drug (specific drug interactions — confirm with trial site).
• You are not eligible if you have had an allergic reaction to tipifarnib (the study drug) or any of its ingredients.
• You are not eligible if you have had an allergic reaction to a group of antifungal medicines called imidazoles (such as clotrimazole, ketoconazole, or miconazole).
• You cannot join if you currently have an infection that is not under control.
• You are not eligible if you have previously had a transplant of a solid organ (such as a kidney, heart, or liver).
• You may not be eligible if the study doctors feel you would not be able to safely follow the study's monitoring and safety requirements.

Important: Always verify eligibility with the trial site directly before applying.